Your trial data is typed in by hand, and cleaned up months later.
Many documents, many owners, and nobody reconciling them. Every disagreement becomes a query, and every day of cleanup delays lock.
queries per Phase III study. Most confirm correct data was correct. 6
What a delay costs over the life of a trial
One layer from every source to your EDC.
One piece of software between every data source and your EDC, running for the whole trial. Your sites are never asked to do anything new.
Check the rulebook
Every study document vs each other and vs FDA, EMA, ICH. Conflicts flagged before enrollment.
Example
Protocol in kilometers, lab manual in miles. Flagged on day one, not month four.Inventory what exists
Records, prior labs, device history and paper, filtered to what counts.
Example
Two years of blood pressure already in the chart get structured and counted.Find the gap
What you need minus what exists = what to collect.
Example
ECGs needed at weeks 4, 12, 24; records cover week 4 for a third of patients.Run the data
Map, convert, check, deliver into the EDC. No retyping.
Example
Watch reports 10 miles; 16.09 km lands in the right field, with the conversion recorded.Watch it daily
Gap re-checked on live data; early warning when an endpoint is at risk.
Example
Site 17's ECG timestamps drift 40 minutes. Flagged in week 3, not at lock.Prove every step
An audit trail for every data point, created or verified.
Example
Where did this glucose value come from? One click: device, time, conversion, reviewer.A source link proves a number is real. It does not prove it is right. Every value carries two things: where it came from, and the rule that produced it, checked against the protocol, the lab manual and the consent form before the first patient. When one of those documents changes, the values it governs are flagged for re-review rather than quietly inheriting the old definition.
What happens at every stage of your study.
Nightingale runs from before the first patient is enrolled until your data is ready for the regulator.
- Protocol, lab and pharmacy manuals, consent and eCRF guidelines reconciled
- Conflicts flagged on day one, not month four
- Existing records structured as real-world evidence
- What your endpoints still need, defined up front
- Every source into your EDC in minutes
- Gap re-checked daily on live data
- Audit trail on every value
- Endpoints met? If not, why
- Submission-ready package
- ~10 days of cleanup instead of ~90 in the illustrative Phase III
Early warnings you would otherwise miss
One site's ECG device timestamps drift from its visit log. Fixed before it becomes a protocol deviation.
Enrollment at four sites is on pace to miss a secondary endpoint. You re-allocate before it costs a quarter.
A lab slip arrives as a photo; the protocol wants a table. It is read, structured and checked against the range.
Every value traces to its source device, time, conversion and reviewer, in one click.
Examples describe what the monitoring stages are built to surface, not results from a specific study.
What each of your teams gets.
Select a team to see what changes for them.
- Sites never asked to do anything new; re-keying goes down
- Daily early warnings on sites and endpoints at risk
- Advance notice while there is still time to act
- Units converted and ranges checked before data reaches the EDC
- Design-origin queries never created
- Every source connected once, delivered in your format
- Audit trail on every value: source, time, conversion, reviewer
- The record of where each value came from and how data moves, produced automatically
- Output in the standard submission format, with a clear trail behind anything AI touched
- GxP vendor audit complete; Part 11 aligned; SOC 2 Type II in progress
- Storage stays with you; your EDC is the system of record
- Fixed, written-down rules; no AI in the data path
- Priced on patients, sources, phase and duration
- Capped at 5% of the trial budget
- Volume discount up to 10% for committed portfolios
Regulators now expect continuous, traceable data.
On 28 April 2026 the FDA launched Real-Time Clinical Trials, and ICH E6(R3) requires you to prove where every value came from.
How many trials this applies to.
How many studies a year this applies to, counted from the public registry rather than estimated from market reports.
Interventional trials of any phase, and device, diagnostic or digital-health studies, that collect data from more than one electronic source and report into a study database.
Studies with wearables, home visits, several labs or many sites, where reconciling sources by hand is the bottleneck.
Registry-only and observational studies with a single data source, where there is little to reconcile.
The trial pool keeps growing: registrations have risen every year since the registry opened in 2000 13. Counts are from public registry data; the in-scope figure is our estimate, not a registry statistic.
A large Phase III, run both ways.
Illustrative: 2,000 patients, 120 sites, 14 sources, three years, scaled from published per-study figures. Design targets under validation, not measured averages.
Priced on the work in your study.
Quotes are reproducible from the same four inputs every time: patients, data sources, phase and duration. Price your study in the calculator below.
Price your trial
Discount grows with each doubling of trials committed, capped at 10%.
Total benefit over the trial
for every dollar spent on Nightingale
Budget from ~$41,000 per patient 10; savings from a data-management team scaled to enrollment 89 and delay days at $55,716 direct and ~$500,000 forgone revenue per day 7, counted in full only for studies that lead to market (15% at Phase I, 35% at Phase II). Days saved is an output, not an input: 14 days of head start before the first patient, plus up to 49 days of cleanup slip avoided, 8 days per connected eSource.
Your second trial costs less effort than your first
Built for a vendor-qualification review.
The standard regulated life-science vendors are held to.
The FDA rule for electronic records.
A record behind every value, from source to submission.
Independent security audit underway.
Not a database. Your EDC remains the system of record.
Fixed rules; the same input always gives the same result.
Delivered in exactly the format you specify.
Neutral to whichever database the study runs.
What your quality team receives
Created if missing, verified if present, and anything wrong flagged.
The E6(R3) diagram of how data moves, produced from the running pipeline.
The rulebook model and pipeline are documented as validated systems.
Directly, or through your CRO.
Work with Nightingale
- A 30-minute portfolio review of your active trials
- A complimentary data flow review of one study
- A written, reproducible quote
- A parallel run on one study before you commit
Ask your CRO for it
- Our CRO partners deliver Nightingale under their own brand
- Same pipeline, audit trail and compliance posture
- Your CRO owns the relationship and the pricing
A 30-minute call on your active trials and where data work is costing you today.
A complimentary hands-on review of one active trial: sources, cleanup steps, and EDC targets.
Written findings and a quote reproducible from patients, sources, phase and duration.
Baseline a comparable trial, run Nightingale alongside on one study, then compare the number of queries, how many are resolved first time, and the lock date.
Live on real patient data.
EmpowerMBC at Emory University, a Gilead-funded oncology study under Dr. Lauren McCullough, is our live deployment and the reference we will put on a call. We will baseline on your study before we claim anything.
$340K contracted across signed agreements: Emory University plus two medical-device trials via Thinq CRO. Harvard iLab company, 11 signed channel partners, and onboarding into the Georgia CTSA Program.
The questions biopharma teams ask.
Keep them. Nightingale is not a database; it delivers into whichever EDC the study runs. A database vendor cannot be neutral to every source and every other EDC, and the sources belong to your sites.
No. Sites are never asked to do anything new and never become our customer. Their re-keying workload goes down.
The GxP vendor audit is complete, Part 11 alignment is in place, SOC 2 Type II is in progress, and an FDA advisory committee member is on the team. After the first trial, later trials skip the security and vendor reviews.
Storage stays with you; your EDC remains the system of record. Our agreements include consented, de-identified derived-data rights, written into the contract so the terms are explicit from the start.
No. AI reads documents and scans to propose values; every value is checked against rules a person wrote and can read, and the part that moves data uses no AI.
A source link proves a value is real. It does not prove it was collected under the definition the analysis assumes. We check the study's documents against each other before enrollment, record which rule produced each value, and flag values for re-review when a document, a definition or a data version changes.
Yes. Existing patient records, prior labs and device history are inventoried and structured as real-world evidence, which the FDA encourages sponsors to use, and counted toward what your endpoints need.
Yes. Start with a complimentary data flow review, then a parallel run on one study against a comparable baseline, comparing the number of queries, how many are resolved first time, and the lock date.
Start with a portfolio review.
Thirty minutes on your active trials and where data work is costing you today.
Pick a time that works for you. We will walk through your trials and where Nightingale would make the biggest difference.
Book a portfolio reviewWhat happens next
A 30-minute call on your active trials.
A complimentary hands-on review of one active trial.
Written findings and a reproducible quote.
Sources behind every figure.
Show all 20 sources
- Tufts Center for the Study of Drug Development (2021): Phase III protocols average 3.6 million data points, three times the volume of ten years earlier.
- Marra C. et al. (2020), npj Digital Medicine: connected digital products in trials grew ~34% per year, 2000-2017.
- Tufts CSDD, eClinical Landscape Study: 257 organizations; median 8.1 days from patient visit to EDC entry.
- Advarra, Study Activation Survey 2023: N>500 sites; ~69% use six or more sponsor systems.
- Garza M. et al. (2026): manual transcription error rate 8.23%; integrated capture showed no detected transcription errors.
- Stokman P. et al. (2021), Journal of the Society for Clinical Data Management 1(1), DOI 10.47912/jscdm.20: 20 Phase III studies, 1,939,606 queries; ~96,980 per study; 42% resulted in a data change.
- Smith Z., DiMasi J., Getz K. (2024), Therapeutic Innovation & Regulatory Science 58(5):855-862: direct cost of trial delay $55,716/day; opportunity cost on the order of $500,000/day.
- Salary.com, US Clinical Data Manager compensation, September 2026: average $144,625, ~$70/hour.
- Vendor-sponsored industry survey, n=88: ~12 hours/week per data manager per study on query and reconciliation work. Indicative.
- Moore T. et al. (2018), JAMA Internal Medicine: median cost per patient in pivotal trials ~$41,117. Per-source and fixed-cost components are estimates.
- IQVIA Institute, Global Use of Medicines: global medicine spending ~$1.6T. Medical device market ~$600B (industry estimate). WHO: global health spending ~$10T.
- Evaluate Pharma / IFPMA: pharmaceutical R&D ~$300B per year; medtech and digital-health R&D ~$50B (estimate). IQVIA Technologies, Veeva and Medidata combined revenue ~$10B.
- ClinicalTrials.gov: more than 35,000 new studies registered per year. The ~20,000 addressable interventional figure is an estimate.
- ClinicalTrials.gov sponsor records: Pfizer ~423 tracked / 251 active; Eli Lilly ~333. Order-of-magnitude proxy.
- ICH E6(R3): §3.16.1(c), §3.16.2(c), §2.12. Step 4 6 Jan 2025; EU 23 Jul 2025; FDA 9 Sep 2025; Annex 2 adopted 3 Jun 2026, effective 15 Jan 2027.
- FDA Digital Health Technologies guidance (Dec 2023); FDA Part 11 Q&A (Oct 2024); FDA and EMA AI principles (Jan 2026); FDA Real-Time Clinical Trials (28 Apr 2026); HHS and ARPA-H SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials), solicitation ARPA-H-SOL-26-164 (30 Sep 2026).
- Disclosed transactions: Change Healthcare/Optum $13B; Datavant/Ciox ~$7B; Komodo Health $3.3B; Flatiron Health/Roche $1.9B; Truveta >$1B; Tempus AI market capitalization ~$10.6B.
- Public revenue multiples: Snowflake at IPO >100× trailing; Palantir ~80× (2025); Cloudflare ~35× (2025); Databricks ~27× (private, 2025).
- Private comparables: a September 2026 software seed round at $7M on $100M post-money with ~$500K lifetime revenue; a clinical-trial software company that raised under $400K in total and sold for roughly half a billion dollars. Details available on request.
- FDA, Considerations for the Design and Conduct of Externally Controlled Trials, draft guidance, February 2023. EMA, qualification opinion on prognostic covariate adjustment using digital twins (PROCOVA), September 2022.
- Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019, JAMA Network Open (2020): of 245,999 interventional studies, 70,329 (28.5%) were industry-sponsored.